ALGN:NSD-Align Technology, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 308.32

Change

-14.25 (-4.42)%

Market Cap

USD 25.41B

Volume

0.58M

Average Target Price

USD 291.55 (-5.44%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign Comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign Moderate, Lite and Express packages, and Invisalign Go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero Scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers; computer-aided design/computer-aided manufacturing services and ancillary products, such as disposable sleeves for the wand; and iTero applications and tools. The company sells its products in the United States, the Netherlands, China, and internationally. Align Technology, Inc. was founded in 1997 and is headquartered in San Jose, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-23 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PODD Insulet Corporation

-2.91 (-1.26%)

USD15.14B 799.00 148.60
LVGO Livongo Health, Inc

-3.80 (-2.75%)

USD13.26B N/A N/A
ABMD Abiomed, Inc

-8.88 (-3.30%)

USD12.12B 79.35 49.21
TNDM Tandem Diabetes Care, Inc

-1.05 (-0.97%)

USD6.60B N/A N/A
BRKR Bruker Corporation

-0.05 (-0.13%)

USD5.94B 37.18 19.02
SDC SmileDirectClub, Inc

-0.83 (-7.42%)

USD4.08B N/A N/A
WMGI Wright Medical Group N.V

-0.02 (-0.07%)

USD3.96B N/A 63.04
IART Integra LifeSciences Holdings ..

-0.31 (-0.68%)

USD3.82B 160.06 27.92
NUVA NuVasive, Inc

-1.99 (-3.90%)

USD2.65B 49.69 18.32
SWAV ShockWave Medical, Inc

-0.87 (-1.24%)

USD2.46B N/A N/A

ETFs Containing ALGN

Symbol Name Weight Mer Price(Change) Market Cap
SPGP Invesco S&P 500 GARP ETF 0.00 % 0.35 %

-1.30 (-2.23%)

USD0.21B
QGRO American Century U.S. Qua.. 0.00 % 0.29 %

-1.06 (-1.99%)

USD0.19B
QQXT First Trust NASDAQ-100 Ex.. 0.00 % 0.60 %

-1.49 (-2.22%)

USD0.10B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.49% 68% D+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.49% 68% D+ 72% C-
Trailing 12 Months  
Capital Gain 68.43% 87% B+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 68.43% 87% B+ 87% B+
Trailing 5 Years  
Capital Gain 441.29% 96% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 441.29% 96% A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 50.39% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.39% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 63.11% N/A N/A N/A N/A
Risk Adjusted Return 79.83% N/A N/A N/A N/A
Market Capitalization 25.41B 100% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 15.24 55% F 56% F
Price/Book Ratio 9.08 28% F 14% F
Price / Cash Flow Ratio 34.01 10% F 9% F
EV/EBITDA 72.02 10% F 9% F
Management Effectiveness  
Return on Equity 80.65% 100% A+ 99% A+
Return on Invested Capital 33.10% 94% A 96% A
Return on Assets 5.27% 90% A- 85% B
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.42 41% F 31% F
Short Percent 4.42% 55% F 43% F
Beta 1.91 15% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.